In the pursuit of creating the UAE’s inaugural homegrown cancer drug, Insilico’s lead candidate, Rentosertib, exhibited positive outcomes in a Phase IIa trial for idiopathic pulmonary fibrosis. Rentosertib displayed promising safety, tolerability, and early efficacy signals, showcasing potential as a breakthrough treatment option for this serious lung disease characterized by lung scarring.
Read more about this — arabianbusiness.com
